Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Apr 16

PMID 32290519

Citations 8

Authors

Yiting Yang

Xiaodong Liu

Affiliations

Soon will be listed here.

Abstract

The pharmacokinetics of a drug is dependent upon the coordinate work of influx transporters, enzymes and efflux transporters (i.e., transporter-enzyme interplay). The transporter-enzyme interplay may occur in liver, kidney and intestine. The influx transporters involving drug transport are organic anion transporting polypeptides (OATPs), peptide transporters (PepTs), organic anion transporters (OATs), monocarboxylate transporters (MCTs) and organic cation transporters (OCTs). The efflux transporters are P-glycoprotein (P-gp), multidrug/toxin extrusions (MATEs), multidrug resistance-associated proteins (MRPs) and breast cancer resistance protein (BCRP). The enzymes related to drug metabolism are mainly cytochrome P450 enzymes (CYP450s) and UDP-glucuronosyltransferases (UGTs). Accumulating evidence has demonstrated that diabetes alters the expression and functions of CYP450s and transporters in a different manner, disordering the transporter-enzyme interplay, in turn affecting the pharmacokinetics of some drugs. We aimed to focus on (1) the imbalance of transporter-CYP450 interplay in the liver, intestine and kidney due to altered expressions of influx transporters (OATPs, OCTs, OATs, PepTs and MCT6), efflux transporters (P-gp, BCRP and MRP2) and CYP450s (CYP3As, CYP1A2, CYP2E1 and CYP2Cs) under diabetic status; (2) the net contributions of these alterations in the expression and functions of transporters and CYP450s to drug disposition, therapeutic efficacy and drug toxicity; (3) application of a physiologically-based pharmacokinetic model in transporter-enzyme interplay.

Citing Articles

Identification of HDAC9 and ARRDC4 as potential biomarkers and targets for treatment of type 2 diabetes.

Liu J, Meng L, Liu Z, Lu M, Wang R Sci Rep. 2024; 14(1):7083.

PMID: 38528189 PMC: 10963792. DOI: 10.1038/s41598-024-57794-5.

Safety and Tolerability of Six Months of Isoniazid Plus Pyridoxine or Three Months of Rifampicin for Tuberculosis among Subjects with Diabetes Mellitus: A Randomized Trial.

Tamez-Torres K, Mongua-Rodriguez N, Ferreyra-Reyes L, Torres-Gonzalez P, Delgado-Sanchez G, Martinez-Hernandez M Microorganisms. 2023; 11(8).

PMID: 37630477 PMC: 10459081. DOI: 10.3390/microorganisms11081917.

Construction and Evaluation of a Novel Organic Anion Transporter 1/3 CRISPR/Cas9 Double-Knockout Rat Model.

Gou X, Ran F, Yang J, Ma Y, Wu X Pharmaceutics. 2022; 14(11).

PMID: 36365126 PMC: 9697873. DOI: 10.3390/pharmaceutics14112307.

The Intestinal and Biliary Metabolites of Ibuprofen in the Rat with Experimental Hyperglycemia.

Mohammed H, Almasi A, Molnar S, Perjesi P Molecules. 2022; 27(13).

PMID: 35807248 PMC: 9268267. DOI: 10.3390/molecules27134000.

Protein phosphatase 2A regulates cytotoxicity and drug resistance by dephosphorylating AHR and MDR1.

Chen L, Guo P, Li W, Jiang X, Zhao Q, Li D J Biol Chem. 2022; 298(5):101918.

PMID: 35405096 PMC: 9118923. DOI: 10.1016/j.jbc.2022.101918.

References

Gawronska-Szklarz B, Musial D, Pawlik A, Paprota B . Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats. Pol J Pharmacol. 2003; 55(4):619-24. View

Aleksunes L, Xu J, Lin E, Wen X, Goedken M, Slitt A . Pregnancy represses induction of efflux transporters in livers of type I diabetic mice. Pharm Res. 2013; 30(9):2209-20. PMC: 3644534. DOI: 10.1007/s11095-013-0981-z. View

Watkins 3rd J, Noda H . Biliary excretion of organic anions in diabetic rats. J Pharmacol Exp Ther. 1986; 239(2):467-73. View

Tucker G, Casey C, Phillips P, Connor H, Ward J, Woods H . Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981; 12(2):235-46. PMC: 1401849. DOI: 10.1111/j.1365-2125.1981.tb01206.x. View

Ueyama J, Wang D, Kondo T, Saito I, Takagi K, Takagi K . Toxicity of diazinon and its metabolites increases in diabetic rats. Toxicol Lett. 2007; 170(3):229-37. DOI: 10.1016/j.toxlet.2007.03.010. View

Gade C, Dalhoff K, Petersen T, Riis T, Schmeltz C, Chabanova E . Higher chlorzoxazone clearance in obese children compared with nonobese peers. Br J Clin Pharmacol. 2018; 84(8):1738-1747. PMC: 6046481. DOI: 10.1111/bcp.13602. View

Varma M, Sarkar M, Kapoor N, Panchagnula R . pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs 1. Simultaneous determination of quinidine and permeability markers in rat in situ perfusion samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 816(1-2):243-9. DOI: 10.1016/j.jchromb.2004.11.040. View

Maximos S, Chamoun M, Gravel S, Turgeon J, Michaud V . Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. Pharmaceutics. 2017; 9(4). PMC: 5750646. DOI: 10.3390/pharmaceutics9040040. View

van Waarde W, Verkade H, Wolters H, Havinga R, Baller J, Bloks V . Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology. 2002; 122(7):1842-52. DOI: 10.1053/gast.2002.33582. View

10.

Chen G, Hu N, Liu L, Xie S, Wang P, Li J . Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. Xenobiotica. 2011; 41(6):494-500. DOI: 10.3109/00498254.2011.558933. View

11.

Xu F, Zhu L, Qian C, Zhou J, Geng D, Li P . Impairment of Intestinal Monocarboxylate Transporter 6 Function and Expression in Diabetic Rats Induced by Combination of High-Fat Diet and Low Dose of Streptozocin: Involvement of Butyrate-Peroxisome Proliferator-Activated Receptor- Activation. Drug Metab Dispos. 2019; 47(6):556-566. DOI: 10.1124/dmd.118.085803. View

12.

Urry E, Jetter A, Landolt H . Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake. Nutr Metab (Lond). 2016; 13:66. PMC: 5052791. DOI: 10.1186/s12986-016-0126-6. View

13.

Bikhazi A, Skoury M, Zwainy D, Jurjus A, Kreydiyyeh S, Smith D . Effect of diabetes mellitus and insulin on the regulation of the PepT 1 symporter in rat jejunum. Mol Pharm. 2005; 1(4):300-8. DOI: 10.1021/mp049972u. View

14.

Adithan C, Srinivas B, Indhiresan J, Shashindran C, Bapna J, Thakur L . Influence of type I and type II diabetes mellitus on phenytoin steady-state levels. Int J Clin Pharmacol Ther Toxicol. 1991; 29(8):310-3. View

15.

Liao M, Flood Nichols S, Ahmed M, Clark S, Hankins G, Caritis S . Effects of Pregnancy on the Pharmacokinetics of Metformin. Drug Metab Dispos. 2020; 48(4):264-271. PMC: 7076518. DOI: 10.1124/dmd.119.088435. View

16.

Ogata M, Iizuka Y, Murata R, Hikichi N . Effect of streptozotocin-induced diabetes on cyclosporin A disposition in rats. Biol Pharm Bull. 1996; 19(12):1586-90. DOI: 10.1248/bpb.19.1586. View

17.

Hu N, Hu M, Duan R, Liu C, Guo H, Zhang M . Increased levels of fatty acids contributed to induction of hepatic CYP3A4 activity induced by diabetes - in vitro evidence from HepG2 cell and Fa2N-4 cell lines. J Pharmacol Sci. 2014; 124(4):433-44. DOI: 10.1254/jphs.13212fp. View

18.

Tramonti G, Xie P, Wallner E, Danesh F, Kanwar Y . Expression and functional characteristics of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes. Am J Physiol Renal Physiol. 2006; 291(5):F972-80. DOI: 10.1152/ajprenal.00110.2006. View

19.

Scott L, Madan E, Valentovic M . Attenuation of cisplatin nephrotoxicity by streptozotocin-induced diabetes. Fundam Appl Toxicol. 1989; 12(3):530-9. DOI: 10.1016/0272-0590(89)90026-2. View

20.

Ding S, Huang J, Qiu H, Chen R, Zhang J, Huang B . Effects of PPARs/20-HETE on the renal impairment under diabetic conditions. Exp Cell Res. 2019; 382(1):111455. DOI: 10.1016/j.yexcr.2019.05.036. View